Advances in Urological Cancer in 2022, from Basic Approaches to Clinical Management-Reference-Cited by-同舟云学术

Advances in Urological Cancer in 2022, from Basic Approaches to Clinical Management

Published:2023-02-23 Issue:5 Volume:15 Page:1422
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Manini Claudia¹²^ORCID,López-Fernández Estíbaliz³⁴^ORCID,López José I.⁵^ORCID,Angulo Javier C.⁶⁷^ORCID

Affiliation:

1. Department of Pathology, San Giovanni Bosco Hospital, 10154 Turin, Italy

2. Department of Sciences of Public Health and Pediatrics, University of Turin, 10124 Turin, Italy

3. FISABIO Foundation, 46020 Valencia, Spain

4. Faculty of Health Sciences, European University of Valencia, 46023 Valencia, Spain

5. Biocruces-Bizkaia Health Research Institute, 48903 Barakaldo, Spain

6. Clinical Department, Faculty of Medical Sciences, European University of Madrid, 28005 Madrid, Spain

7. Department of Urology, University Hospital of Getafe, 28907 Madrid, Spain

Abstract

This Special Issue includes 12 articles and 3 reviews dealing with several basic and clinical aspects of prostate, renal, and urinary tract cancer published during 2022 in Cancers, and intends to serve as a multidisciplinary chance to share the last advances in urological neoplasms [...]

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

https://www.mdpi.com/2072-6694/15/5/1422/pdf

Reference53 articles.

1. Pellerin, E., Pellerin, F.A., Chabaud, S., Pouliot, F., Bolduc, S., and Pelletier, M. (2022). Bisphenols A and S alter the bioenergetics and behaviours of normal urothelial and bladder cancer cells. Cancers, 14.

2. Endocrine-disrupting effects of bisphenols on urological cancers;Pellerin;Environ. Res.,2021

3. Reader, K.L., John-McHaffie, S., Zellhuber-McMillan, S., Jowett, T., Mottershead, D.G., Cunliffe, H.E., and Gold, E.J. (2023). Activin B and activin C have opposing effects on prostate cancer progression and cell growth. Cancers, 15.

4. Activins and activin antagonists in the prostate and prostate cancer;Gold;Mol. Cell. Endocrinol.,2012

5. Tossetta, G., Fantone, S., Gesuita, R., Goteri, G., Senzacqua, M., Marcheggiani, F., Tiano, L., Marzioni, D., and Mazzucchelli, R. (2022). Ciliary neurotrophic factor modulates multiple downstream signaling pathways in prostate cancer inhibiting cell invasiveness. Cancers, 14.